Table 4.
Probability to obtain a tumor size reduction ≥70% after neoadjuvant chemotherapy according to clinical–pathological and IHC features (logistic regression analysis)
| Characteristic | Size reduction ≥70%
|
||
|---|---|---|---|
| HR | 95% CI | P-value | |
| Age (years) | |||
| <50 | 1 | ||
| ≥50 | 17.0 | 1.59–181.36 | 0.01 |
| ER (%) | |||
| <70 | 1 | ||
| ≥70 | 0.14 | 0.02–1.05 | 0.05 |
| PgR (%) | |||
| <10 | 1 | ||
| ≥10 | 0.09 | 0.009–0.95 | 0.04 |
| TLE3 | |||
| Positive | 1 | ||
| Negative | 12.5 | 0.81–166.66 | 0.07 |
| TOP2A | |||
| Negative | 1 | ||
| Positive | 9.0 | 0.88–91.25 | 0.06 |
| Ki-67 | |||
| <50% | 1 | ||
| ≥50% | 4.50 | 0.65–31.08 | 0.12 |
| HER2 | |||
| Negative | 1 | ||
| Positive | 0.90 | 0.08–9.97 | 0.93 |
| Triple-negative | |||
| No | 1 | ||
| Yes | 3.16 | 0.39–25.57 | 0.27 |
| Grade | |||
| 1–2 | 1 | ||
| 3 | 2.40 | 0.36–15.94 | 0.36 |
| Pathological (ypT) stage | |||
| T2 | 1 | ||
| T3–T4 | 3.16 | 0.39–25.57 | 0.27 |
| LVSI | |||
| Negative | 1 | ||
| Positive | 0.28 | 0.04–1.92 | 0.19 |
| Type of lesion | |||
| Not multicentric | 1 | ||
| Multicentric | 3.21 | 0.43–23.78 | 0.25 |
| Tumor histology | |||
| Ductal | 1 | ||
| Others | 0.28 | 0.04–1.92 | 0.19 |
Abbreviations: CI, confidence interval; ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; HR, hazard ratio; LVSI, lymphovascular space invasion; PgR, progesterone receptor; TLE3, transducin-like enhancer of split 3; TOP2A, topoisomerase II alpha.